Brought to you by 
CMIC gets Japanese rights to Dyax's DX88 for angioedema
01 Nov 2010
Executive Summary
CMIC Co. Ltd. (CRO with an orphan drug-development arm) licensed Japanese rights to Dyax Corp.'s (therapeutics for unmet medical needs) subcutaneous DX88 (ecallantide) for hereditary angioedema (HAE) and other types of angioedema.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CMIC gets Japanese rights to Dyax's DX88 for angioedema
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice